BioWorld tracked 143 clinical trial readouts across phases I through III in April 2026, down from 209 in March, but roughly in line with 152 in February and 144 in January. By phase, April’s readouts included 47 from phase I, 59 from phase II and 37 in phase III. Among phase III programs, 15 trials reported positive results and two failed to meet primary endpoints.

The BioWorld Drug Developers Index (BDDI) outpaced both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average throughout the first four months of 2026. Starting the year in step with the broader indices, the BDDI pulled ahead steadily – climbing 4.41% year-to-date through January, 6.42% through February and 7.73% through March, before finishing April up 10.69% for the year.

The U.S. FDA granted 14 approvals in April 2026, down from March’s 19 but broadly in line with the historical range for the month.

Biopharma stocks, as measured on the BioWorld Biopharmaceutical Index, underperformed both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average through the first four months of 2026.

Biopharma deal value through the first four months of 2026 reached $92.98 billion, outpacing every recent year and running well ahead of 2025’s strong $79.82 billion over the same period. January and February each cleared $30 billion, while March and April totaled $18.05 billion and $13.3 billion, respectively.

Med-tech M&A value through the first four months of 2026 reached $62.01 billion, the highest total for the period since 2022’s $73.58 billion and a dramatic step up from 2025’s $20.03 billion and 2024’s $5.74 billion over the same period.

Biopharma deal value through the first four months of 2026 reached $92.98 billion, outpacing every recent year and running well ahead of 2025’s strong $79.82 billion over the same period. January and February each cleared $30 billion, while March and April totaled $18.05 billion and $13.3 billion, respectively.

Biopharma financing activity is continuing its rebound in early 2026 compared to the past several years. Total funding reached $38.66 billion in the first four months of 2026, more than doubling 2025’s $15.85 billion in the same period and also exceeding 2022 and 2023. While still below the peak years of 2021 and 2024, when financings topped $50 billion in the period, the 2026 total shows a strong recovery.

Med-tech financing activity in the first four months of 2026 reached $10.05 billion, similar to 2025’s $10.31 billion and 2022’s $10.62 billion. While below the peak years of 2019-2021, when financings were above $15 billion in the time period, total value is still above the levels seen in 2023-2024. April saw $1.51 billion raised, compared to $2.44 billion in March, $4.55 billion in February and $1.52 billion in January.

Med-tech financing activity in the first four months of 2026 reached $10.05 billion, similar to 2025’s $10.31 billion and 2022’s $10.62 billion. While below the peak years of 2019-2021, when financings were above $15 billion in the time period, total value is still above the levels seen in 2023-2024. April saw $1.51 billion raised, compared to $2.44 billion in March, $4.55 billion in February and $1.52 billion in January.